Q-omics provides the consensus-scored ANKRD18DP profile across patient tissues and cancer cell-line models. ANKRD18DP expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ANKRD18DP is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, ANKRD18DP RNA expression shows 11,559 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRC, and TGCT as cancer lineages where ANKRD18DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD18DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD18DP survival associations across molecular data types. ANKRD18DP RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD18DP RNA expression–survival associations across cancer types. High ANKRD18DP expression shows unfavorable associations in COAD, KIRP, KICH and UVM, but favorable associations in HNSC and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ANKRD18DP RNA expression.
This table summarizes ANKRD18DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD18DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD18DP shows lower tumor expression in LIHC and higher tumor expression in KIRC, KICH, KIRP, HNSC and LUSC. The KIRC box plot shows higher ANKRD18DP RNA expression in tumor versus normal tissue (log2 FC = +0.141, t-test p < 0.001).
This table shows molecular features associated with ANKRD18DP in patient tissues and cancer cell lines. In patient samples, ANKRD18DP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD18DP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
